You searched for: mdma (Lettiska - Engelska)

mdma
methylenedioxymethamphetamine

vidējās tīrības jeb mdma satura diapazons
range of mean purity or mdma content

nav skaidru ekstazī tablešu mdma satura tendenču.
there are no clear trends in the mdma content of ecstasy tablets.

pmma toksicitāte varētu būt līdzīga pma un mdma toksicitātei.
pmma seems to have a similar toxicity to pma and mdma.

turcijā tikai 23 % analizēto tablešu saturēja mdma līdzīgas vielas.
in turkey, only 23 % of the tablets analysed were found to contain mdma-like substances.

var pieņemt, ka mcpp pievienošanas mērķis varētu būt mdma iedarbības pastiprināšana vai uzlabošana.
it might be assumed that the addition of mcpp is intended to potentiate or ameliorate the effects of mdma.

2003. gadā vidējais mdma saturs ekstazītabletēs bija robežās no 54 līdz 78 mg (81).
ketamine and ghb, both of which underwent riskassessment in 2000, continue to be monitored through the ews.

uz tabletēm, kas satur amfetamīnu vai metamfetamīnu, var būt tādi paši logotipi kā uz mdma un citām ekstazī tabletēm.
tablets containing either amphetamine or methamphetamine may carry logos similar to those seen on mdma and other ecstasy tablets.

tomēr 2008. gadā mcpp joprojām bija visplašāk pieejamā jaunā sintētiskā narkotika nelegālo narkotiku tirgū, kas sastopama viena vai kombinācijā ar mdma.
for example, online shops based in ireland, poland and the united kingdom were offering ‘retro pills’, which are purported to contain 1-(4-fluorophenyl) piperazine (pfpp), a substance described as having mild hallucinogenic and strong euphoric effects.

eiropas savienībā pmma līdz šim lietots kopā ar pma tabletēs, ko pazīst ar nosaukumu ecstasy (mdma).
within the european union, pmma has always been consumed with pma in tablets taken as "ecstasy" (mdma).

mdma satursekstazī tabletēs atšķiras dažādās partijās (pat tabletēs arvienādu zīmolu) gan dažādās valstīs, gan vienas valstsietvaros.
information on various othersubstances, including some cathinones (such as substitutedpyrrolidines), was also collected and exchanged.however, the european commission and the european council were not asked to sanction a risk assessment ofany new substance because there was insufficientevidence of individual/public health or social risks.

4-mta ir amfetamīna atvasinājums, par kuru noskaidrots, ka tas rada lielāku akūtas iedarbības risku, nekā mdma (3,4-metilēndioksimetamfetamīns), tostarp blakusparādības un pārdozēšanu.
4-mta is an amphetamine derivative which appears to carry a higher risk of acute effects than mdma (3,4-methylenedioxymethamphetamine) including adverse reactions and overdosage.